Business
Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management
NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administration First-in-human Phase 1 study is expected to initiate in the first half of 2026, pending regulatory clearance Preparations for dose-ranging Phase 2 study of NPM-139 to occur in parallel with Phase 1 study ALAMEDA, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing novel, ultra long-acting dru
About this update from Vivani Medical, Inc.
[{"type":"image","alt":"Vivani Medical, Inc.","displaySize":"","headline":null,"caption":"Vivani Medical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/c23870f4ae46a8fd33cfe7a0a48ef637"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aU1HV9H8XgPgL8OdypT.mA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c23870f4ae46a8fd33cfe7a0a48ef637","width":300,"height":300}},"lazy":false},{"type":"text","content":"NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administration","length":96,"tagName":"p"},{"type":"text","content":"First-in-human Phase 1 study is expected to initiate in the first half of 2026, pending regulatory clearance","length":108,"tagName":"p"},{"type":"text","content":"Preparations for dose-ranging Phase 2 study of NPM-139 to occur in parallel with Phase 1 study","length":94,"tagName":"p"},{"type":"text","content":"ALAMEDA, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing novel, ultra long-acting drug implants, today announced plans to initiate a Phase 1 clinical study in the NPM-139 semaglutide implant program in the first half of 2026, pending regulatory clearance. The Company is also preparing to initiate a Phase 2 clinical study of NPM-139 pending enabling results from the Phase 1 study and regulatory feedback. The NPM-139 clinical program will evaluate the Company’s investigational semaglutide implant for chronic weight management in patients who are either obese or overweight with a related comorbidity.","length":724,"tagName":"p"},{"type":"text","content":"“Recent promising results from LIBERATE-1™, the first-in-human study of NPM-115, an exenatide implant utilizing NanoPortal™ technology, combined with positive preclinical weight loss data with NPM-139, compel us to move forward aggressively with clinical development of NPM-139. The Phase 1 study, designed to evaluate the safety, tolerability and pharmacokinetic profile of the semaglutide implant and to enable a Phase 2 efficacy study, is expected to initiate in the first half of 2026, pending regulatory clearance,” said Vivani President and Chief Executive Officer Adam Mendelsohn, Ph.D. ...